Literature DB >> 28910146

Management of Acute Respiratory Distress Syndrome and Refractory Hypoxemia. A Multicenter Observational Study.

Erick H Duan1,2,3, Neill K J Adhikari4,5, Frederick D'Aragon2,6,7, Deborah J Cook1,2,3, Sangeeta Mehta5,8, Waleed Alhazzani1,2,3, Ewan Goligher5,9, Emmanuel Charbonney10, Yaseen M Arabi11, Tim Karachi1,12, Alexis F Turgeon13,14, Lori Hand2,15, Qi Zhou2, Peggy Austin2, Jan Friedrich5,16, Francois Lamontagne6,7, François Lauzier14, Rakesh Patel17, John Muscedere18, Richard Hall19, Pierre Aslanian20, Thomas Piraino3,21, Martin Albert22, Sean M Bagshaw23, Mike Jacka23, Gordon Wood24, William Henderson25, Delbert Dorscheid26, Niall D Ferguson5,9, Maureen O Meade1,2,15.   

Abstract

RATIONALE: Clinicians' current practice patterns in the management of acute respiratory distress syndrome (ARDS) and refractory hypoxemia are not well described.
OBJECTIVES: To describe mechanical ventilation strategies and treatment adjuncts for adults with ARDS, including refractory hypoxemia.
METHODS: This was a prospective cohort study (March 2014-February 2015) of mechanically ventilated adults with moderate-to-severe ARDS requiring an FiO2 of 0.50 or greater in 24 intensive care units.
RESULTS: We enrolled 664 patients: 222 (33%) with moderate and 442 (67%) with severe ARDS. On Study Day 1, mean Vt was 7.5 (SD = 2.1) ml/kg predicted body weight (n = 625); 80% (n = 501) received Vt greater than 6 ml/kg. Mean positive end-expiratory pressure (PEEP) was 10.5 (3.7) cm H2O (n = 653); 568 patients (87%) received PEEP less than 15 cm H2O. Treatment adjuncts were common (n = 440, 66%): neuromuscular blockers (n = 276, 42%), pulmonary vasodilators (n = 118, 18%), prone positioning (n = 67, 10%), extracorporeal life support (n = 29, 4%), and high-frequency oscillatory ventilation (n = 29, 4%). Refractory hypoxemia, defined as PaO2 less than 60 mm Hg on FiO2 of 1.0, occurred in 138 (21%) patients. At onset of refractory hypoxemia, mean Vt was 7.1 (SD = 2.0) ml/kg (n = 124); 95 patients (77%) received Vt greater than 6 ml/kg. Mean PEEP was 12.1 (SD = 4.4) cm H2O (n = 133); 99 patients (74%) received PEEP less than 15 cm H2O. Among patients with refractory hypoxemia, 91% received treatment adjuncts (126/138), with increased use of neuromuscular blockers (n = 87, 63%), pulmonary vasodilators (n = 57, 41%), and prone positioning (n = 32, 23%).
CONCLUSIONS: Patients with moderate-to-severe ARDS receive treatment adjuncts frequently, especially with refractory hypoxemia. Paradoxically, therapies with less evidence supporting their use (e.g., pulmonary vasodilators) were over-used, whereas those with more evidence (e.g., prone positioning, neuromuscular blockade) were under-used. Patients received higher Vts and lower PEEP than would be suggested by the evidence.

Entities:  

Keywords:  acute respiratory distress syndrome; lung protective ventilation; neuromuscular blocking agents; prone positioning; refractory hypoxemia

Mesh:

Substances:

Year:  2017        PMID: 28910146     DOI: 10.1513/AnnalsATS.201612-1042OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  18 in total

1.  Early Use of Adjunctive Therapies for Pediatric Acute Respiratory Distress Syndrome: A PARDIE Study.

Authors:  Courtney M Rowan; Margaret J Klein; Deyin Doreen Hsing; Mary K Dahmer; Philip C Spinella; Guillaume Emeriaud; Amanda B Hassinger; Byron E Piñeres-Olave; Heidi R Flori; Bereketeab Haileselassie; Yolanda M Lopez-Fernandez; Ranjit S Chima; Steven L Shein; Aline B Maddux; Jon Lillie; Ledys Izquierdo; Martin C J Kneyber; Lincoln S Smith; Robinder G Khemani; Neal J Thomas; Nadir Yehya
Journal:  Am J Respir Crit Care Med       Date:  2020-06-01       Impact factor: 21.405

2.  Hospital Mechanical Ventilation Volume and Patient Outcomes: Too Much of a Good Thing?

Authors:  Anuj B Mehta; Allan J Walkey; Douglas Curran-Everett; Daniel Matlock; Ivor S Douglas
Journal:  Crit Care Med       Date:  2019-03       Impact factor: 7.598

3.  Patients with acute respiratory distress syndrome exhibit increased stromelysin1 activity in the blood samples.

Authors:  Sandeep Artham; Arti Verma; Andrea Sikora Newsome; Payaningal R Somanath
Journal:  Cytokine       Date:  2020-04-06       Impact factor: 3.861

4.  Adjunct and rescue therapies for refractory hypoxemia: prone position, inhaled nitric oxide, high frequency oscillation, extra corporeal life support.

Authors:  Niall D Ferguson; Claude Guérin
Journal:  Intensive Care Med       Date:  2018-01-18       Impact factor: 17.440

5.  Hospital-Level Availability of Prone Positioning in Massachusetts ICUs.

Authors:  Anica C Law; Natalia Forbath; Sharon O'Donoghue; Jennifer P Stevens; Allan J Walkey
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

6.  Procedure Codes for Intubated Prone Positioning: A Turn for the Better.

Authors:  Anica C Law; Nicholas A Bosch; Allan J Walkey
Journal:  Ann Am Thorac Soc       Date:  2022-10

7.  Comparing Prone Positioning Use in COVID-19 Versus Historic Acute Respiratory Distress Syndrome.

Authors:  Chad H Hochberg; Kevin J Psoter; Sarina K Sahetya; Eric P Nolley; Shakir Hossen; William Checkley; Meeta P Kerlin; Michelle N Eakin; David N Hager
Journal:  Crit Care Explor       Date:  2022-05-13

Review 8.  Beyond Low Tidal Volume Ventilation: Treatment Adjuncts for Severe Respiratory Failure in Acute Respiratory Distress Syndrome.

Authors:  Vikram Fielding-Singh; Michael A Matthay; Carolyn S Calfee
Journal:  Crit Care Med       Date:  2018-11       Impact factor: 7.598

9.  A survey on the practices and capabilities in the management of respiratory failure in South East England.

Authors:  Abhishek Jha; Francesco Vasques; Barnaby Sanderson; Kathleen Daly; Guy Glover; Nicholas Ioannou; Duncan Wyncoll; Peter Sherren; Chris Langrish; Chris Meadows; Andrew Retter; Richard Paul; Nicholas A Barrett; Luigi Camporota
Journal:  J Intensive Care Soc       Date:  2020-06-01

10.  Treatment with 7% and 10% CO2 enhanced expression of IL-1β, TNF-α, and IL-6 in hypoxic cultures of human whole blood.

Authors:  Hongguang Ding; Ya Li; Xusheng Li; Xinqiang Liu; Shenglong Chen; Mengting Liu; Hongke Zeng
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.